Experience with lenalidomide in an Austrian non-study population with advanced myelofibrosis

Wiener Klinische Wochenschrift

Volumn 125, Issue 7-8, 2013, Pages 196-199

  Burgstaller, Sonja ^a   Fridrik, Michael ^b   Hojas, Sabine ^c   Kühr, Thomas ^a   Ludwig, Heinz ^d   Mayrbäurl, Beate ^a   Pöhnl, Rainer ^e   Pötscher, Michael ^f   Schlögl, Ernst ^g   Zauner, Daniela ^f   Thaler, Josef ^f   Gisslinger, Heinz ^h  

^a Klinikum Wels Grieskirchen GmbH   (Austria)

^b KEPLER UNIVERSITY HOSPITAL   (Austria)

^c Interne Abteilung   (Austria)

^d WILHELMINEN HOSPITAL   (Austria)

^e Medizinische Abteilung   (Austria)

^f Clinical Trial Unit Wels   (Austria)

^g HANUSCH HOSPITAL   (Austria)

^h MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Efficacy; Lenalidomide; Myelofibrosis; Nonstudy population

Indexed keywords

LENALIDOMIDE; DRUG DERIVATIVE; IMMUNOLOGIC FACTOR; THALIDOMIDE;

ADULT; AGED; ARTICLE; AUSTRIA; BODY WEIGHT DISORDER; BRONCHITIS; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG EFFICACY; DYNAMIC INTERNATIONAL PROGNOSTIC SCORING SYSTEM; FEMALE; HIGH RISK POPULATION; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; LEUKOPENIA; MALE; MIDDLE AGED; MUSCLE CRAMP; MYELOFIBROSIS; PERIPHERAL EDEMA; PHARYNGITIS; POLYCYTHEMIA VERA; PULMONARY HYPERTENSION; RISK ASSESSMENT; THROMBOCYTHEMIA; THROMBOCYTOPENIA; URINARY TRACT INFECTION; VERY ELDERLY; ANEMIA; CHEMICALLY INDUCED DISORDER; DOSE RESPONSE; MYELOID METAPLASIA; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; COMPLICATION; PRIMARY MYELOFIBROSIS;

AGED; AGED, 80 AND OVER; ANEMIA; AUSTRIA; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; LEUKOPENIA; MALE; MIDDLE AGED; PRIMARY MYELOFIBROSIS; THALIDOMIDE; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 84891420367     PISSN: 00435325     EISSN: 16137671     Source Type: Journal    
DOI: 10.1007/s00508-013-0345-z     Document Type: Article

References (11)

1. Tefferi A, Thiele J, Orazi A, Kvasnicka HM, Barbui T, Hanson CA, Verstovsek S, Birgegard G, Mesa R, Reilly JT, Gisslinger H, Vannucchi AM, Cervantes F, Finazzi G, Hoffman R, Gilliland DG, Bloomfield CD, Vardiman JW. Proposal and rationale for provision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood. 2007;110:1092-7.
2. Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E, Vannucchi AM, Mesa RA, Demory JL, Barosi G, Rumi E, Tefferi A. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113:2895-2901.
3. Cervantes F, Mesa R, Barosi G. New and old treatment modalities in primary myelofibrosis. Cancer J. 2007;13:377-83.
4. Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, McQuitty M, Hunter DS, Levi R, Knoops L, Cervantes F, Vanucchi AM, Barbui T, Barosi G. JAK Inhibition with ruxolitinib verus best available therapy for myelofibrosis. N Engl J Med. 2012;366:778-98.
5. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Grupts V, DipPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, Harvey JH, Arcasoy MJ, Hexner E, Lyons RM, Paquette R, Raza A, Vaddi K, Ericson-Viitanen S, Koumenis IL, Sun W, Sandor V, Kantarjian HM. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366:799-807.
6. Tefferi A, Cortes J, Verstovsek S, Mesa RA, Thomas D, Lasho TL, Hogan WJ, Litzow MR, Allred JB, Jones D, Byrne C, Zeldis JB, Ketterling RP, McClure RF, Giles F, Kantarjian HM. Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood. 2006;108:1158-64.
7. Quintas-Cardama A, Kantarjian HM, Manshouri T, Thomas D, Cortes J, Ravandi F, Garcia-Manero G, Ferrajoli A, Bueso- Ramos C, Verstovsek S. Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis. J Clin Oncol. 2009;27;4760-6.
8. Mesa RA, Yao X, Cripe LD, Li CY, Litzow M, Paietta E, Rowe JM, Tefferi A, Tallman MS. Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903. Blood. 2010;116:4436-8.
9. Tefferi A, Barosi G, Mesa RA, Cervantes F, Deeg HJ, Reilly JT, Verstovsek S, Dupriez B, Silver RT, Odenike O, Cortes J, Wadleigh M, Solberg SA, Camoriano JK, Gisslinger H, Noel P, Thiele J, Vardiman JW, Hoffman R, Cross NC, Gilliland DG, Kantarjian H. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood. 2006;108:1497-1503.
10. Burgstaller S, Wimmer S, Mayrbäurl B, Hoebling W, Thaler J. Coexistence of primary myelofibrosis and chronic lymphocytic leukaemia-treatment of two different diseases with one agent. Blood Cancer J. 2011;1:e20; doi:10.1038/ bcj.2011.18.
11. Jabbour E, Thomas D, Kantarjian H, Zhou L, Pierce S, Cortes J, Verstovsek S. Comparison of thalidomide and lenalidomide as therapy for myelofibrosis. Blood. 2011;118:899-902.